A rationale for the use of β-blockers as standard treatment for heart failure

American Heart Journal

Volumn 139, Issue 3, 2000, Pages 511-521

  Metra, Marco ^a   Nodari, Savina ^b   D'Aloia, Antonio ^b   Bontempi, Luca ^b   Boldi, Emiliano ^b   Dei Cas, Livio ^b  

^a SPEDALI CIVILI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; PLACEBO;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; SYMPATHETIC TONE;

EID: 0034099293     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90096-6     Document Type: Article

References (50)

1. 1. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. 2. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of 3 conceptual models of the disease. Am J Cardiol 1993;71:3C-11C.
3. 3. Eichorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-96.
4. 4. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998;352(suppl I);SI8-14.
5. 5. Francis GS, Benedict C, Johnstone DE, et al, for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
6. 6. Bristow MR. Mechanism of action of β-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L.
7. 7. Fowler MB, Laser JA, Hopkins GL, et al. Assessment of the β-adrenergic receptor pathways in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation 1986;74:1290-302.
8. 8. White M, Yanowitz F, Gilbert EM, et al. Role of β-adrenergic downregulation in the peak exercise response of subjects with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995;76:1271-6.
9. 9. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80:15L-25L.
10. 10. Doughty RN, Whalley GA, Gamble G, et al, on behalf of the Australia/New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
11. 11. Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 1998;98:1329-34.
12. 12. Feuerstein G, Yue T-L, Ma X, et al. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41(suppl 1):17-24.
13. 13. Sabbah HN, Sharov VG, Goussev A, et al. Long-term therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. Circulation 1998;98(suppl I):I-364.
14. 14. Bristow MR, Gilbert EM, Lowes BD, et al. Changes in myocardial gene expression associated with β-blocker related improvement in ventricular systolic function. Circulation 1997;96:I-92.
15. 15. Lechat PP, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
16. 16. Bristow MR, O'Connell JB, Gilbert EM, et al, for the Bucindolol Investigators. Dose response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42.
17. 17. Bristow MR, Gilbert EM, Abraham WT, et al, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
18. 18. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
19. 19. Anderson JL, Gilbert EM, O'Connell JB, et al. Long-term (2 year) beneficial effects of β-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991;17:1373-81.
20. 20. Waagstein F, Caidahl K, Wallentin I, et al. Long term β-blockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
21. 21. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
22. 22. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51.
23. 23. Metra M, Nodari S, D'Aloia A, et al. Effects of chronic β-blockade on the haemodynamics and functional capacity of patients with heart failure: a randomized comparison between metoprolol and carvedilol [abstract]. Eur Heart J 1998;19(suppl):307.
24. 24. Di Lenarda A, Sabbadini G, Salvatore L, et al, and the Heart-Muscle Disease Study Group. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926-34.
25. 25. Metra M, Nodari S, D'Aloia A, et al. Effects of neurohumoral antagonism on symptoms and quality of life in heart failure. Eur Heart J 1998;19(suppl B):B25-35.
26. 26. Gilbert EM, Gilbert EM, Anderson JL, et al. Long-term β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
27. 27. Metra M, Nardi M, Giubbini R, et al. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopothy. J Am Coll Cardiol 1994;24:1678-7.
28. 28. Waagstein F, Bristow MR, Swedberg K, et al, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
29. 29. Packer M, Colucci WS, Sackner-Bernstein J, et al, for the PRECISE study group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996;94:2793-9.
30. 30. Colucci WS, Packer M, Bristow MR, et al, for the US Carvedilol Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
31. 31. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
32. 32. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
33. 33. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
34. 34. Australia New Zealand Heart Failure Research Collaborative Group. Randomised placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-80.
35. 35. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
36. 36. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
37. 37. White M, Rouleau JL, Pericak D, et al, on behalf of the RESOLVD Study Group. Effects of metoprolol-CR in patients with ischemic and dilated cardiomyopathy: the RESOLVD pilot study (phase II) [abstract]. Eur Heart J 1998;19(suppl):308.
38. 38. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-9.
39. 39. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
40. 40. BEST Steering Committee. Design of the β-Blocker Evaluation of Survival Trial (BEST). Am J Cardiol 1995;75:1220-3.
41. 41. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(suppl J):8-16.
42. 2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96:1914-22.
43. 43. Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation 1998;98(suppl I):I-378-9.
44. 1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation 1991;84:1732-40.
45. 45. Doughty RN, Rodgers A, Sharpe N, et al. Effects of β-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-5.
46. 46. Heidenreich PA, Lee TT, Massie BM. Effect of β-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
47. 47. Yusuf S, Peto R, Lewis J, et al. β-Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
48. 48. Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled randomized trial. Circulation 1997;96:183-91.
49. 49. Lechat P, Escolano S, Golmard JL, et al, on behalf of the CIBIS Investigators. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997;96:2197-205.
50. 50. Packer M, Cohn JN, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus Recommendations for the Management of Chronic Heart Failure, II: management of heart failure: approaches to the prevention of heart failure. Am J Cardiol 1999;83(2A):9A-38A.